glycopyrronium tosylate: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Journey	QBREXZA	glycopyrronium tosylate	CLOTH;TOPICAL	210361	NDA	Journey Medical Corporation	69489-411-05	5 POUCH in 1 CARTON (69489-411-05) / 2.8 g in 1 POUCH (69489-411-51)	2018-06-28
Journey	QBREXZA	glycopyrronium tosylate	CLOTH;TOPICAL	210361	NDA	Journey Medical Corporation	69489-411-30	30 POUCH in 1 CARTON (69489-411-30) / 2.8 g in 1 POUCH (69489-411-01)	2018-06-28
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

WHAT IS THE GLOBAL SUPPLY CHAIN FOR GLYCOPYRRONIUM TOSYLATE?

The global supply chain for glycopyrronium tosylate is concentrated among a limited number of manufacturers, primarily in China and India. These suppliers provide the active pharmaceutical ingredient (API) to drug formulators worldwide. The market is characterized by established players with significant production capacity, though potential risks include geopolitical factors, regulatory scrutiny, and dependence on specific geographic regions. Key players and their reported capacities, where publicly available, are detailed below.

WHO ARE THE MAJOR GLYCOPYRRONIUM TOSYLATE MANUFACTURERS?

The manufacturing of glycopyrronium tosylate API is dominated by a few key suppliers, with Chinese and Indian companies holding the largest market share. These manufacturers adhere to Good Manufacturing Practices (GMP) to ensure API quality and consistency for pharmaceutical use.

Chinese Manufacturers

China hosts several significant producers of glycopyrronium tosylate. Companies like Shanxi Ciyuan Biotech Co., Ltd. and Hunan Huayang Pharmaceutical Co., Ltd. are prominent suppliers. These companies typically offer the API in bulk quantities, often meeting various international pharmacopeia standards.

Shanxi Ciyuan Biotech Co., Ltd. is recognized for its API production capabilities, including glycopyrronium tosylate. Their production processes aim for high purity and compliance with global pharmaceutical standards.
Hunan Huayang Pharmaceutical Co., Ltd. is another established Chinese API manufacturer with glycopyrronium tosylate in its product portfolio. They serve both domestic and international markets, supplying to drug developers and generic manufacturers.

Indian Manufacturers

India is another critical hub for glycopyrronium tosylate API manufacturing. Companies such as Divi's Laboratories and Laurus Labs are major players in the API space, with robust production infrastructure and a strong global presence.

Divi's Laboratories is a leading API manufacturer globally, known for its large-scale production and diverse product offerings. While specific glycopyrronium tosylate capacity is not always disclosed, their overall manufacturing prowess suggests significant capability.
Laurus Labs is a research-driven pharmaceutical company that manufactures APIs and finished dosages. They have expanded their API portfolio, and glycopyrronium tosylate is among their offerings, catering to a global customer base.

Other Regional Suppliers

While China and India are the primary sources, some manufacturers in other regions may also supply glycopyrronium tosylate, often serving niche markets or specific customer requirements. These suppliers might include companies based in Europe or North America, though their market share for bulk API is generally smaller compared to Asian counterparts. The exact number and capacity of these smaller suppliers are not always readily available in public disclosures.

WHAT ARE THE REGULATORY CONSIDERATIONS FOR GLYCOPYRRONIUM TOSYLATE SUPPLY?

Regulatory compliance is paramount in the pharmaceutical supply chain. Suppliers of glycopyrronium tosylate must adhere to stringent quality standards and regulatory requirements set by health authorities worldwide.

Good Manufacturing Practices (GMP)

All API manufacturers, including those for glycopyrronium tosylate, must comply with GMP regulations. These standards ensure that products are consistently produced and controlled according to quality standards appropriate for their intended use. This includes:

Facility Standards: Manufacturing sites must meet specific architectural and engineering requirements to prevent contamination and ensure product integrity.
Process Validation: Production processes must be validated to demonstrate that they consistently yield a product of the required quality.
Quality Control: Robust quality control systems, including testing of raw materials, in-process materials, and final API, are mandatory.
Documentation: Comprehensive record-keeping for all manufacturing and quality control activities is essential for traceability and audits.

Pharmacopeia Standards

Glycopyrronium tosylate API must meet the specifications outlined in major pharmacopeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (EP), and Japanese Pharmacopoeia (JP). These standards define the acceptable limits for purity, impurities, identity, and other critical quality attributes. Suppliers must provide Certificates of Analysis (CoA) demonstrating compliance with the relevant pharmacopeia.

Drug Master Files (DMFs)

API manufacturers often file Drug Master Files (DMFs) with regulatory agencies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). A DMF contains detailed information about the manufacturing, processing, packaging, and storage of the API. This allows drug product manufacturers to reference the DMF in their marketing applications without disclosing proprietary manufacturing information to their customers. The completeness and acceptance of a DMF are critical for suppliers seeking to serve regulated markets.

Environmental, Social, and Governance (ESG) Compliance

Increasingly, pharmaceutical companies are scrutinizing their supply chains for ESG compliance. This includes assessing suppliers' environmental impact, labor practices, and corporate governance. Suppliers of glycopyrronium tosylate may face questions regarding their waste management, energy consumption, ethical sourcing, and adherence to international labor laws.

WHAT ARE THE SUPPLY CHAIN RISKS AND MITIGATION STRATEGIES?

The reliance on a concentrated supplier base for glycopyrronium tosylate presents several supply chain risks. Understanding and proactively addressing these risks is crucial for pharmaceutical companies.

Geopolitical and Trade Risks

Concentration in Specific Regions: The heavy reliance on China and India for API manufacturing makes the supply chain vulnerable to geopolitical tensions, trade disputes, or changes in export policies in these regions.
Mitigation:
- Dual Sourcing: Engaging with multiple qualified suppliers, ideally in different geographic regions, can reduce dependence on a single source.
- Geographic Diversification: Identifying and qualifying suppliers in alternative regions, even if at a higher cost, can provide a strategic hedge.
- Inventory Management: Maintaining adequate safety stock of critical raw materials and finished API can buffer against short-term supply disruptions.

Regulatory and Quality Risks

GMP Non-Compliance: Findings of GMP non-compliance during regulatory inspections can lead to import alerts or product recalls, disrupting supply.
Impurity Profiling: Changes in synthetic routes or inadequate control over impurities can lead to batch rejections and regulatory challenges.
Mitigation:
- Rigorous Supplier Qualification: Implementing thorough due diligence processes, including on-site audits and review of quality systems, is essential.
- Continuous Monitoring: Regularly reviewing supplier regulatory filings, audit reports, and quality metrics provides early warning of potential issues.
- Collaborative Quality Agreements: Establishing clear quality agreements with suppliers that define responsibilities, change control processes, and communication protocols is vital.

Production Capacity and Lead Time Risks

Sudden Demand Surges: Unexpected increases in demand for glycopyrronium tosylate-containing products can strain existing production capacities.
Long Lead Times: API manufacturing often involves complex multi-step syntheses, leading to significant lead times for production and delivery.
Mitigation:
- Long-Term Supply Agreements: Negotiating long-term contracts with preferred suppliers can secure dedicated capacity and more predictable pricing.
- Capacity Planning: Working closely with suppliers to understand their capacity utilization and expansion plans helps in forecasting future availability.
- Forecasting Accuracy: Improving demand forecasting accuracy for finished drug products allows for better planning of API procurement.

Intellectual Property Risks

Patent Expirations: The expiration of patents covering glycopyrronium tosylate itself or key intermediates can lead to increased competition and potential quality variations from new entrants.
Mitigation:
- Early Engagement with IP Counsel: Understanding the patent landscape for the API and its manufacturing processes is crucial for strategic planning.
- Supplier Audits of IP Compliance: Ensuring that suppliers are not infringing on existing intellectual property rights during their manufacturing processes.

WHAT ARE THE KEY MARKET TRENDS AND FUTURE OUTLOOK?

The market for glycopyrronium tosylate is influenced by the demand for its end-use applications, primarily in respiratory and gastrointestinal treatments.

Growing Demand for Respiratory Therapies

Glycopyrronium tosylate is a component in bronchodilators used for chronic obstructive pulmonary disease (COPD) and asthma. The increasing prevalence of these respiratory conditions globally, driven by aging populations and environmental factors, fuels demand for related APIs.

COPD Prevalence: According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD), COPD is projected to become the third-leading cause of death worldwide by 2030 [1]. This trend directly translates to increased demand for bronchodilator therapies.
Asthma Management: Asthma remains a significant global health issue, affecting millions. Effective long-acting muscarinic antagonists (LAMAs) like glycopyrronium tosylate are integral to its management.

Advancements in Drug Delivery Systems

Innovations in drug delivery, particularly dry powder inhalers (DPIs) and metered-dose inhalers (MDIs), require high-quality, consistently manufactured APIs. The particle size, morphology, and purity of glycopyrronium tosylate are critical for optimal performance in these advanced delivery devices. Suppliers who can consistently meet these tight specifications are favored.

Generic Competition and Pricing Pressures

As off-patent products, glycopyrronium tosylate-containing medications face competition from generic manufacturers. This dynamic exerts downward pressure on API pricing, necessitating cost-effective manufacturing processes from suppliers. Companies that can achieve economies of scale and optimize their production efficiently are better positioned to compete.

Emerging Markets and New Indications

The expansion of healthcare access in emerging markets presents new growth opportunities. Additionally, ongoing research into new indications or novel formulations for glycopyrronium tosylate could create future demand.

Projected Market Growth Drivers:

Increased COPD and Asthma Diagnosis Rates: Improved diagnostic capabilities and greater awareness of respiratory diseases.
Aging Global Population: Older individuals are more susceptible to chronic respiratory conditions.
Technological Advancements in Inhaler Devices: Demand for high-performance APIs compatible with next-generation inhalers.
Development of Combination Therapies: Glycopyrronium tosylate is often used in combination with other bronchodilators or corticosteroids, driving demand for multiple APIs.

KEY TAKEAWAYS

The global supply of glycopyrronium tosylate API is concentrated in China and India, with a limited number of key manufacturers.
Regulatory compliance, particularly GMP and pharmacopeia standards, is non-negotiable for API suppliers serving pharmaceutical markets.
Supply chain risks include geopolitical instability, trade policy changes, and potential quality deviations, necessitating strategies like dual sourcing and robust supplier qualification.
Demand for glycopyrronium tosylate is driven by the increasing prevalence of respiratory diseases like COPD and asthma, alongside advancements in drug delivery technologies.
Future growth is anticipated from emerging markets, new therapeutic indications, and combination therapies.

FAQS

Is glycopyrronium tosylate produced by any manufacturers in North America or Europe?

While the bulk of glycopyrronium tosylate API manufacturing is concentrated in Asia, some smaller-scale production or specialized synthesis may occur in North America or Europe. These suppliers typically cater to specific niche markets or offer custom synthesis services, rather than competing on large-volume commodity supply. Information on these regional suppliers is less publicly available compared to major Asian manufacturers.

What are the typical lead times for ordering glycopyrronium tosylate API from major suppliers?

Typical lead times for ordering glycopyrronium tosylate API can range from 8 to 16 weeks. This duration accounts for production scheduling, multi-step synthesis, quality control testing, and logistics. For very large orders or custom specifications, lead times can extend beyond this range. It is advisable for drug formulators to engage with suppliers early in their product development cycle to confirm current lead times and capacity.

How is the purity of glycopyrronium tosylate API typically measured and validated?

The purity of glycopyrronium tosylate API is rigorously measured and validated using a combination of analytical techniques. High-performance liquid chromatography (HPLC) is commonly employed to determine the assay (percentage of glycopyrronium tosylate) and to identify and quantify related substances (impurities). Other validated tests include:

Mass Spectrometry (MS): For structural confirmation and impurity identification.
Nuclear Magnetic Resonance (NMR) Spectroscopy: For structural elucidation and authentication.
Karl Fischer Titration: To determine water content.
Loss on Drying (LOD): To measure volatile matter.
Residue on Ignition (ROI): To determine inorganic impurities.

Compliance with specified limits for each of these parameters, as defined by pharmacopeias like USP or EP, is essential.

What are the implications of recent regulatory actions or recalls related to glycopyrronium tosylate API?

Recent regulatory actions or recalls related to glycopyrronium tosylate API, if any, can have significant implications for the supply chain. Such events, often triggered by GMP non-compliance or identified impurities, can lead to import alerts, halting shipments from affected manufacturers. This can cause immediate supply shortages for drug product manufacturers reliant on that specific API source. It also necessitates a heightened level of scrutiny for other suppliers from the same region or those using similar manufacturing processes. Drug formulators may need to quickly qualify alternative suppliers or accelerate the development of secondary sources to mitigate the impact of such disruptions.

Can glycopyrronium tosylate API be sourced from suppliers without DMF filings?

While it is technically possible to source glycopyrronium tosylate API from suppliers who have not filed a Drug Master File (DMF) with regulatory agencies, this is generally not advisable for products intended for regulated markets such as the United States or Europe. DMFs provide regulatory authorities with confidential, detailed information about the API manufacturing process, which is essential for the approval of finished drug products. Without a DMF, drug product manufacturers would need to conduct extensive internal validation and provide significant proprietary manufacturing details in their own regulatory submissions, which is often unfeasible and costly. For pharmaceutical applications, sourcing from suppliers with accepted DMFs is standard practice.

[1] Global Initiative for Chronic Obstructive Lung Disease. (n.d.). GOLD Executive Summary. Retrieved from https://goldcopd.org/gold-reports/

Suppliers and packagers for generic pharmaceutical drug: glycopyrronium tosylate